| December 2018 |
| 19 Dec |
Company Statement : Biosimilar Trastuzumab Co-Developed by Biocon Receives Approval in the EU |
 |
| 17 Dec |
Company Statement : Biocon's APIs Manufacturing Facility in Telangana Completes U.S. FDA Inspection with No 483 Observations |
|
| 02 Dec |
Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children's Park to the Community |
|
| November 2018 |
| 30 Nov |
Company Statement : Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU |
|
| 12 Nov |
Company Statement : Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations |
|
| October 2018 |
| 30 Oct |
Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018
|
|
| 25 Oct |
Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%
|
|
| 19 Oct |
Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
|
|
| September 2018 |
| 22 Sept |
Company Statement : Biocon’s Drug Substance Facility in Bangalore completes US FDA Inspection with No observations
|
|
| 21 Sept |
Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
|
|
| July 2018 |
| 26 July |
Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%;
EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr
|
|
| 04 July |
Company Statement: Biocon's Sterile Drug Product facility receives EU GMP Certification
|
|
| June 2018 |
| 28 June |
Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA
|
|
| 28 June |
Company Statement: Biocon retains economic interest in Etanercept collaboration with Mylan
|
|
| 23 June |
Company Statement: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA
|
|
| 04-05 June |
U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
|
|
| 04 June |
Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018 |
|
| 02 June |
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA |
|
| 02 June |
Company Statement : Biocon Update on Insulin Glargine
|
|
| May 2018 |
| 02 May |
Company Statement: Biocon Regulatory Audit Update |
|
| April 2018 |
| 26 Apr |
Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr |
|
| 18 Apr |
Kiran Mazumdar-Shaw #1 Business Captain in
'The Medicine Maker 2018 Power List' |
|
| 11 Apr |
Company Statement: Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU |
|
| March 2018 |
| 28 Mar |
Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for SemgleeTM Biosimilar Insulin Glargine |
|
| 13 Mar |
Update on Company Statement on US-FDA Inspection at Biocon Malaysia |
|
| February 2018 |
| 21 Feb |
Company Statement on US-FDA Inspection at Biocon Malaysia |
|
| January 2018 |
| 29 Jan |
Mylan and Biocon Receive Positive CHMP Opinion for SemgleeTM, Biosimilar Insulin Glargine |
|
| 24 Jan |
Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore |
|
| 18 Jan |
Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars |
|
